Predict your next investment

HEALTHCARE | Biotechnology
exicuretx.com

See what CB Insights has to offer

Founded Year

2011

Stage

Loan | IPO

Total Raised

$33.48M

Market Cap

0.04B

Stock Price

0.47

Revenue

$0000 

About Exicure

Exicure, formerly AuraSense Therapeutics, develops a new class of immunomodulatory and gene silencing drugs against validated targets. The company's 3-dimensional, spherical nucleic acid (SNA) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. Its lead programs address diseases from inflammatory disorders to oncology. SNA constructs overcome one of the most difficult obstacles to nucleic acid therapeutics: safe and effective delivery into cells and tissues. SNA constructs exhibit transfection efficiency into numerous cell and tissue types including the skin without carriers or transfection agents. Moreover, SNAs can be used as potent immunotherapeutic agents for the treatment of cancer or infectious disease.

Exicure Headquarter Location

8045 Lamon Avenue Suite 410

Skokie, Illinois, 60077,

United States

847-673-1700

Latest Exicure News

Exicure Investor Alert

Nov 28, 2021

Exicure Investor Alert Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Exicure To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - November 28, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Exicure, Inc. ("Exicure" or the "Company") (NASDAQ: XCUR). If you suffered losses exceeding $50,000 investing in Exicure stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/XCUR . There is no cost or obligation to you. Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia. On November 15, 2021, Exicure filed a Form 12b-25 with the SEC stating that it could not timely file its quarterly report for the period ended September 30, 2021. It explained that the Company was investigating "a claim made by a former Company senior researcher regarding alleged improprieties that researcher claims to have committed with respect to the Company's XCUR-FXN preclinical program for the treatment of Friedreich's ataxia." On this news, Exicure's stock declined nearly 29% during intraday trading on November 16, 2021, thereby injuring investors. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com ). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner. To view the source version of this press release, please visit https://www.newsfilecorp.com/release/105350 Sign up for Alerts Sign up to receive news releases by email for Faruqi & Faruqi LLP or all companies belonging to the Banking/Financial Services industry.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Exicure

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Exicure is included in 3 Expert Collections, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharmaceuticals

14,140 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

R

Regenerative Medicine

1,767 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

Exicure Patents

Exicure has filed 23 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • Clusters of differentiation
  • Immune system
patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/12/2019

9/21/2021

Immune system, Immunology, Clusters of differentiation, Molecular biology, Allergology

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

9/12/2019

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

9/21/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Immune system, Immunology, Clusters of differentiation, Molecular biology, Allergology

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Exicure Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Exicure Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.